Epigral Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Epigral Limited has confirmed to the stock exchanges that there is no deviation or variation in the use of funds raised through its Qualified Institutional Placement (QIP) for the quarter ended 31st March 2025. The company had raised Rs. 333.05 crore through the QIP on 24th October 2024. The funds were allocated across four purposes: Rs. 250 crore for repayment of borrowings, Rs. 30 crore for capital expenditure on fixed assets, Rs. 44.72 crore for general corporate purposes, and Rs. 8.33 crore for issue expenses. The full amount of Rs. 333.05 crore has been utilized in line with the originally stated objects. The statement was reviewed by the Audit Committee on 5th May 2025, and CARE Ratings Limited served as the monitoring agency. The auditors had no comments on the usage.
This is a routine compliance filing and reflects positively on corporate governance. Full and intended use of QIP funds, with no deviation, reassures shareholders that management has deployed the raised capital as promised, including significant debt reduction.